Share Price and Basic Stock Data
Last Updated: November 14, 2025, 11:31 am
| PEG Ratio | -10.18 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Chandra Bhagat Pharma Ltd operates within the pharmaceuticals sector, focusing on the production and distribution of various pharmaceutical products. As of the latest market data, the company’s stock price stood at ₹41.1, with a market capitalization of ₹31.0 Cr. The company has shown a significant increase in sales, reporting ₹119.26 Cr in the September 2023 quarter, up from ₹44.27 Cr in September 2022. This reflects a year-on-year growth of approximately 169%. However, sales for March 2025 are expected to decline to ₹21.80 Cr, indicating potential volatility in revenue streams. The company’s operating profit margin (OPM) has fluctuated, standing at -1.19% currently, showcasing challenges in managing operational costs effectively. Furthermore, the cash conversion cycle (CCC) is reported at 110.17 days, suggesting inefficiencies in converting investments into cash flow. Overall, while the company has experienced notable revenue growth recently, it faces challenges that could impact future performance.
Profitability and Efficiency Metrics
Chandra Bhagat Pharma’s profitability metrics reveal a mixed performance. The company reported a net profit of ₹0.86 Cr for the latest fiscal year, translating to a net profit margin of 0.98%, which is relatively low compared to sector averages. The return on equity (ROE) is recorded at 2.41%, while the return on capital employed (ROCE) stood at 6.00%, both indicating underperformance in generating returns for shareholders. The operating profit has shown a distressing trend, with the latest quarter reflecting an operating loss of ₹5.00 Cr, a significant drop from the ₹1.80 Cr profit reported in March 2023. Additionally, the interest coverage ratio (ICR) is at 2.09x, suggesting that the company can cover its interest obligations, albeit with limited cushion. These figures highlight the need for improved operational efficiency and cost management to enhance profitability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Chandra Bhagat Pharma Ltd exhibits both strengths and vulnerabilities. The company reported total borrowings of ₹20.86 Cr against reserves of ₹22.42 Cr, indicating a manageable debt-to-equity ratio of 0.69. This suggests that the company is not over-leveraged, providing a level of financial stability. However, total liabilities have surged to ₹101.53 Cr, raising concerns about long-term sustainability. The current ratio is recorded at 1.41x, indicating a healthy short-term liquidity position. The company’s book value per share has increased to ₹39.72, reflecting a gradual build-up of shareholder equity. Additionally, the enterprise value (EV) is at ₹59.68 Cr, which, when juxtaposed with net operating revenue, indicates an EV/Net Operating Revenue ratio of 0.68, suggesting that the stock may be undervalued relative to its revenues. Overall, while the balance sheet shows some resilience, the increasing liabilities warrant close monitoring.
Shareholding Pattern and Investor Confidence
Chandra Bhagat Pharma’s shareholding pattern reveals a significant level of promoter confidence, with promoters holding 71.20% of the company as of March 2025. This is a slight increase from 68.24% in March 2023, indicating stability and commitment from the founding members. Foreign Institutional Investors (FIIs) hold a minor stake of 0.61%, while Domestic Institutional Investors (DIIs) hold none, reflecting a lack of institutional backing. The public shareholding stands at 28.18%, with the total number of shareholders increasing to 316, which may enhance liquidity in the stock. However, the low institutional interest could be a red flag for potential investors, suggesting that the market may not view the company favorably. The concentration of ownership among promoters may also raise concerns about governance and minority shareholder interests, which could affect overall investor confidence.
Outlook, Risks, and Final Insight
The outlook for Chandra Bhagat Pharma Ltd appears cautiously optimistic, yet it is fraught with risks. The significant revenue growth in recent quarters is encouraging, but the decline in operating profit and net margins raises questions about the sustainability of this growth. Key risks include high operational costs, as evidenced by the negative OPM, and potential liquidity challenges stemming from increasing liabilities. Additionally, the company’s reliance on a limited number of shareholders could pose governance risks. To strengthen its market position, Chandra Bhagat Pharma must focus on improving operational efficiencies and enhancing profit margins. If the company can successfully navigate these challenges and capitalize on its revenue growth, it may position itself for improved financial health and investor confidence moving forward. However, without substantial improvements in profitability and operational management, the risks may outweigh potential benefits.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Chandra Bhagat Pharma Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 147 Cr. | 117 | 247/84.3 | 32.6 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.52 Cr. | 1.84 | 4.33/1.82 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,854 Cr. | 446 | 479/192 | 101 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 45.9 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 38.1 Cr. | 26.0 | 29.1/17.0 | 90.6 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,339.74 Cr | 1,190.20 | 53.71 | 201.98 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 22.36 | 48.33 | 43.15 | 50.93 | 44.27 | 75.40 | 119.26 | 102.11 | 64.92 | 21.80 |
| Expenses | 20.71 | 46.67 | 41.53 | 49.87 | 43.24 | 73.60 | 124.26 | 104.15 | 66.11 | 22.06 |
| Operating Profit | 1.65 | 1.66 | 1.62 | 1.06 | 1.03 | 1.80 | -5.00 | -2.04 | -1.19 | -0.26 |
| OPM % | 7.38% | 3.43% | 3.75% | 2.08% | 2.33% | 2.39% | -4.19% | -2.00% | -1.83% | -1.19% |
| Other Income | 0.02 | 0.46 | 0.47 | 1.15 | 0.60 | 0.19 | 7.01 | 4.32 | 3.07 | 2.45 |
| Interest | 1.62 | 1.86 | 1.45 | 1.63 | 1.04 | 1.15 | 0.66 | 0.73 | 0.85 | 1.10 |
| Depreciation | 0.01 | 0.02 | 0.06 | 0.06 | 0.05 | 0.22 | 0.43 | 0.21 | 0.41 | 0.54 |
| Profit before tax | 0.04 | 0.24 | 0.58 | 0.52 | 0.54 | 0.62 | 0.92 | 1.34 | 0.62 | 0.55 |
| Tax % | 25.00% | 33.33% | 24.14% | 30.77% | 31.48% | 14.52% | 31.52% | 33.58% | -11.29% | 69.09% |
| Net Profit | 0.03 | 0.16 | 0.43 | 0.36 | 0.37 | 0.54 | 0.63 | 0.90 | 0.68 | 0.17 |
| EPS in Rs | 0.04 | 0.21 | 0.57 | 0.48 | 0.49 | 0.72 | 0.83 | 1.19 | 0.90 | 0.23 |
Last Updated: May 31, 2025, 6:33 am
Below is a detailed analysis of the quarterly data for Chandra Bhagat Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 21.80 Cr.. The value appears to be declining and may need further review. It has decreased from 64.92 Cr. (Sep 2024) to 21.80 Cr., marking a decrease of 43.12 Cr..
- For Expenses, as of Mar 2025, the value is 22.06 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 66.11 Cr. (Sep 2024) to 22.06 Cr., marking a decrease of 44.05 Cr..
- For Operating Profit, as of Mar 2025, the value is -0.26 Cr.. The value appears strong and on an upward trend. It has increased from -1.19 Cr. (Sep 2024) to -0.26 Cr., marking an increase of 0.93 Cr..
- For OPM %, as of Mar 2025, the value is -1.19%. The value appears strong and on an upward trend. It has increased from -1.83% (Sep 2024) to -1.19%, marking an increase of 0.64%.
- For Other Income, as of Mar 2025, the value is 2.45 Cr.. The value appears to be declining and may need further review. It has decreased from 3.07 Cr. (Sep 2024) to 2.45 Cr., marking a decrease of 0.62 Cr..
- For Interest, as of Mar 2025, the value is 1.10 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.85 Cr. (Sep 2024) to 1.10 Cr., marking an increase of 0.25 Cr..
- For Depreciation, as of Mar 2025, the value is 0.54 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.41 Cr. (Sep 2024) to 0.54 Cr., marking an increase of 0.13 Cr..
- For Profit before tax, as of Mar 2025, the value is 0.55 Cr.. The value appears to be declining and may need further review. It has decreased from 0.62 Cr. (Sep 2024) to 0.55 Cr., marking a decrease of 0.07 Cr..
- For Tax %, as of Mar 2025, the value is 69.09%. The value appears to be increasing, which may not be favorable. It has increased from -11.29% (Sep 2024) to 69.09%, marking an increase of 80.38%.
- For Net Profit, as of Mar 2025, the value is 0.17 Cr.. The value appears to be declining and may need further review. It has decreased from 0.68 Cr. (Sep 2024) to 0.17 Cr., marking a decrease of 0.51 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.23. The value appears to be declining and may need further review. It has decreased from 0.90 (Sep 2024) to 0.23, marking a decrease of 0.67.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:40 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 48.01 | 61.13 | 79.84 | 89.79 | 97.06 | 106.28 | 93.97 | 70.70 | 94.04 | 119.67 | 221.37 | 86.72 | 47.35 |
| Expenses | 46.18 | 58.13 | 76.42 | 85.41 | 92.47 | 101.69 | 90.85 | 67.02 | 91.20 | 116.33 | 228.41 | 88.14 | 45.94 |
| Operating Profit | 1.83 | 3.00 | 3.42 | 4.38 | 4.59 | 4.59 | 3.12 | 3.68 | 2.84 | 3.34 | -7.04 | -1.42 | 1.41 |
| OPM % | 3.81% | 4.91% | 4.28% | 4.88% | 4.73% | 4.32% | 3.32% | 5.21% | 3.02% | 2.79% | -3.18% | -1.64% | 2.98% |
| Other Income | 0.64 | 0.31 | 0.38 | 0.49 | 0.67 | 0.44 | 0.44 | 0.48 | 1.62 | 0.29 | 11.33 | 5.49 | 2.79 |
| Interest | 1.88 | 2.35 | 2.83 | 3.81 | 3.67 | 4.09 | 3.11 | 3.76 | 3.24 | 2.20 | 1.39 | 1.95 | 1.91 |
| Depreciation | 0.17 | 0.26 | 0.24 | 0.14 | 0.06 | 0.05 | 0.03 | 0.12 | 0.12 | 0.27 | 0.64 | 0.95 | 1.15 |
| Profit before tax | 0.42 | 0.70 | 0.73 | 0.92 | 1.53 | 0.89 | 0.42 | 0.28 | 1.10 | 1.16 | 2.26 | 1.17 | 1.14 |
| Tax % | 16.67% | 38.57% | 50.68% | 27.17% | 32.68% | 22.47% | 26.19% | 32.14% | 27.27% | 21.55% | 32.74% | 26.50% | |
| Net Profit | 0.35 | 0.43 | 0.35 | 0.66 | 1.03 | 0.69 | 0.31 | 0.19 | 0.80 | 0.91 | 1.53 | 0.86 | 0.62 |
| EPS in Rs | 8.37 | 10.29 | 8.37 | 15.79 | 24.64 | 10.29 | 0.41 | 0.25 | 1.06 | 1.21 | 2.03 | 1.14 | 0.83 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 22.86% | -18.60% | 88.57% | 56.06% | -33.01% | -55.07% | -38.71% | 321.05% | 13.75% | 68.13% | -43.79% |
| Change in YoY Net Profit Growth (%) | 0.00% | -41.46% | 107.18% | -32.51% | -89.07% | -22.06% | 16.36% | 359.76% | -307.30% | 54.38% | -111.92% |
Chandra Bhagat Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | -2% |
| 3 Years: | -3% |
| TTM: | -61% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 23% |
| 3 Years: | 2% |
| TTM: | -44% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 4% |
| 3 Years: | -23% |
| 1 Year: | -39% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 3% |
| 3 Years: | 4% |
| Last Year: | 3% |
Last Updated: September 5, 2025, 2:51 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 65.15 | 70.99 | 66.15 | 79.92 | 67.16 | 90.32 | 54.50 | 79.61 | 58.22 | 24.98 | 65.05 | 151.31 |
| Inventory Days | 161.44 | 176.71 | 122.83 | 132.66 | 144.60 | 173.53 | 186.75 | 214.70 | 153.25 | 99.59 | 15.23 | 3.44 |
| Days Payable | 53.01 | 43.18 | 32.81 | 80.69 | 68.58 | 117.37 | 53.13 | 78.51 | 11.98 | 10.62 | 23.21 | 44.58 |
| Cash Conversion Cycle | 173.59 | 204.52 | 156.17 | 131.89 | 143.18 | 146.48 | 188.12 | 215.80 | 199.49 | 113.95 | 57.06 | 110.17 |
| Working Capital Days | 148.78 | 166.47 | 133.63 | 124.96 | 138.50 | 83.39 | 147.60 | 177.18 | 103.94 | 75.00 | 35.89 | 115.28 |
| ROCE % | 11.68% | 10.44% | 10.40% | 14.77% | 17.42% | 13.13% | 6.97% | 7.44% | 8.62% | 7.13% | 7.95% | 6.00% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.14 | 2.03 | 1.20 | 1.06 | 0.25 |
| Diluted EPS (Rs.) | 1.14 | 2.03 | 1.20 | 1.06 | 0.25 |
| Cash EPS (Rs.) | 2.40 | 2.88 | 1.55 | 1.22 | 0.29 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 39.72 | 38.45 | 36.42 | 35.35 | 34.30 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 39.72 | 38.45 | 36.42 | 35.35 | 34.30 |
| Revenue From Operations / Share (Rs.) | 114.93 | 293.40 | 158.61 | 124.68 | 93.70 |
| PBDIT / Share (Rs.) | 5.39 | 5.69 | 4.79 | 5.69 | 1.05 |
| PBIT / Share (Rs.) | 4.13 | 4.84 | 4.44 | 5.53 | 1.01 |
| PBT / Share (Rs.) | 1.54 | 3.00 | 1.54 | 1.45 | 0.36 |
| Net Profit / Share (Rs.) | 1.14 | 2.03 | 1.20 | 1.05 | 0.25 |
| PBDIT Margin (%) | 4.68 | 1.93 | 3.01 | 4.56 | 1.12 |
| PBIT Margin (%) | 3.58 | 1.64 | 2.79 | 4.43 | 1.07 |
| PBT Margin (%) | 1.34 | 1.02 | 0.97 | 1.16 | 0.39 |
| Net Profit Margin (%) | 0.98 | 0.69 | 0.75 | 0.84 | 0.26 |
| Return on Networth / Equity (%) | 2.86 | 5.27 | 3.29 | 2.98 | 0.73 |
| Return on Capital Employeed (%) | 9.64 | 11.86 | 9.95 | 12.12 | 1.95 |
| Return On Assets (%) | 0.84 | 1.50 | 1.49 | 1.09 | 0.26 |
| Long Term Debt / Equity (X) | 0.07 | 0.04 | 0.14 | 0.20 | 0.36 |
| Total Debt / Equity (X) | 0.69 | 0.56 | 0.68 | 0.74 | 0.96 |
| Asset Turnover Ratio (%) | 0.85 | 2.73 | 1.80 | 1.30 | 0.96 |
| Current Ratio (X) | 1.41 | 1.38 | 2.19 | 1.86 | 2.13 |
| Quick Ratio (X) | 1.40 | 1.26 | 1.11 | 0.96 | 1.06 |
| Inventory Turnover Ratio (X) | 0.00 | 1.54 | 0.53 | 0.07 | 0.23 |
| Interest Coverage Ratio (X) | 2.09 | 3.09 | 1.65 | 1.40 | 1.65 |
| Interest Coverage Ratio (Post Tax) (X) | 1.44 | 2.10 | 1.41 | 1.26 | 1.39 |
| Enterprise Value (Cr.) | 59.68 | 83.14 | 85.69 | 99.92 | 52.54 |
| EV / Net Operating Revenue (X) | 0.68 | 0.37 | 0.71 | 1.06 | 0.74 |
| EV / EBITDA (X) | 14.68 | 19.38 | 23.71 | 23.26 | 66.02 |
| MarketCap / Net Operating Revenue (X) | 0.45 | 0.32 | 0.61 | 0.91 | 0.42 |
| Price / BV (X) | 1.32 | 2.47 | 2.66 | 3.22 | 1.15 |
| Price / Net Operating Revenue (X) | 0.45 | 0.32 | 0.61 | 0.91 | 0.42 |
| EarningsYield | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Chandra Bhagat Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 5. It has decreased from 2.03 (Mar 24) to 1.14, marking a decrease of 0.89.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 5. It has decreased from 2.03 (Mar 24) to 1.14, marking a decrease of 0.89.
- For Cash EPS (Rs.), as of Mar 25, the value is 2.40. This value is below the healthy minimum of 3. It has decreased from 2.88 (Mar 24) to 2.40, marking a decrease of 0.48.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 39.72. It has increased from 38.45 (Mar 24) to 39.72, marking an increase of 1.27.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 39.72. It has increased from 38.45 (Mar 24) to 39.72, marking an increase of 1.27.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 114.93. It has decreased from 293.40 (Mar 24) to 114.93, marking a decrease of 178.47.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 5.39. This value is within the healthy range. It has decreased from 5.69 (Mar 24) to 5.39, marking a decrease of 0.30.
- For PBIT / Share (Rs.), as of Mar 25, the value is 4.13. This value is within the healthy range. It has decreased from 4.84 (Mar 24) to 4.13, marking a decrease of 0.71.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.54. This value is within the healthy range. It has decreased from 3.00 (Mar 24) to 1.54, marking a decrease of 1.46.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 2. It has decreased from 2.03 (Mar 24) to 1.14, marking a decrease of 0.89.
- For PBDIT Margin (%), as of Mar 25, the value is 4.68. This value is below the healthy minimum of 10. It has increased from 1.93 (Mar 24) to 4.68, marking an increase of 2.75.
- For PBIT Margin (%), as of Mar 25, the value is 3.58. This value is below the healthy minimum of 10. It has increased from 1.64 (Mar 24) to 3.58, marking an increase of 1.94.
- For PBT Margin (%), as of Mar 25, the value is 1.34. This value is below the healthy minimum of 10. It has increased from 1.02 (Mar 24) to 1.34, marking an increase of 0.32.
- For Net Profit Margin (%), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 5. It has increased from 0.69 (Mar 24) to 0.98, marking an increase of 0.29.
- For Return on Networth / Equity (%), as of Mar 25, the value is 2.86. This value is below the healthy minimum of 15. It has decreased from 5.27 (Mar 24) to 2.86, marking a decrease of 2.41.
- For Return on Capital Employeed (%), as of Mar 25, the value is 9.64. This value is below the healthy minimum of 10. It has decreased from 11.86 (Mar 24) to 9.64, marking a decrease of 2.22.
- For Return On Assets (%), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 5. It has decreased from 1.50 (Mar 24) to 0.84, marking a decrease of 0.66.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 0.2. It has increased from 0.04 (Mar 24) to 0.07, marking an increase of 0.03.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.69. This value is within the healthy range. It has increased from 0.56 (Mar 24) to 0.69, marking an increase of 0.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.85. It has decreased from 2.73 (Mar 24) to 0.85, marking a decrease of 1.88.
- For Current Ratio (X), as of Mar 25, the value is 1.41. This value is below the healthy minimum of 1.5. It has increased from 1.38 (Mar 24) to 1.41, marking an increase of 0.03.
- For Quick Ratio (X), as of Mar 25, the value is 1.40. This value is within the healthy range. It has increased from 1.26 (Mar 24) to 1.40, marking an increase of 0.14.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 4. It has decreased from 1.54 (Mar 24) to 0.00, marking a decrease of 1.54.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.09. This value is below the healthy minimum of 3. It has decreased from 3.09 (Mar 24) to 2.09, marking a decrease of 1.00.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.44. This value is below the healthy minimum of 3. It has decreased from 2.10 (Mar 24) to 1.44, marking a decrease of 0.66.
- For Enterprise Value (Cr.), as of Mar 25, the value is 59.68. It has decreased from 83.14 (Mar 24) to 59.68, marking a decrease of 23.46.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1. It has increased from 0.37 (Mar 24) to 0.68, marking an increase of 0.31.
- For EV / EBITDA (X), as of Mar 25, the value is 14.68. This value is within the healthy range. It has decreased from 19.38 (Mar 24) to 14.68, marking a decrease of 4.70.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.45. This value is below the healthy minimum of 1. It has increased from 0.32 (Mar 24) to 0.45, marking an increase of 0.13.
- For Price / BV (X), as of Mar 25, the value is 1.32. This value is within the healthy range. It has decreased from 2.47 (Mar 24) to 1.32, marking a decrease of 1.15.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.45. This value is below the healthy minimum of 1. It has increased from 0.32 (Mar 24) to 0.45, marking an increase of 0.13.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Chandra Bhagat Pharma Ltd:
- Net Profit Margin: 0.98%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 9.64% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 2.86% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.44
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.4
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 48.6 (Industry average Stock P/E: 53.71)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.69
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.98%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 323-F Bhagat Bhuvan, Mumbai Maharashtra 400019 | compliancecbc@gmail.com http://www.cbcpharma.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Hemant Chandravadan Bhagat | Chairman & Managing Director |
| Mr. Pranav Hemant Bhagat | Whole Time Director |
| Mrs. Prachi Pranav Bhagat | Director & CFO |
| Mr. Ravindra Gajanan Awati | Independent Director |
| Ms. Abha Praveen Doshi | Independent Director |